CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
92 hedge funds and large institutions have $334M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 4 closing their positions.
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
183% more capital invested
Capital invested by funds: $118M → $334M (+$216M)
46% more funds holding
Funds holding: 63 → 92 (+29)
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
22% more call options, than puts
Call options by funds: $3.15M | Put options by funds: $2.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$12.7M |
| 2 |
BL
Bleichroeder LP
New York
|
+$10.8M |
| 3 |
Millennium Management
New York
|
+$5.88M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.82M |
| 5 |
Two Sigma Investments
New York
|
+$4.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$12.3M |
| 2 |
ACM
Altium Capital Management
New York
|
-$5.62M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$5.55M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.89M |
| 5 |
Renaissance Technologies
New York
|
-$728K |
CTIC Hedge Fund Activity: Q1 2022 in Review
92 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2022, worth a combined $334M — up 183% from $118M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CTIC positions and 4 closed out — a net gain of 29 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was Lion Point Capital, adding an estimated $12.7M. The largest seller was Stonepine Capital Management, cutting an estimated $12.3M.
- 92 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2022, up from 63 in Q4 2021.
- Funds reported $334M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2022, up 183% quarter-over-quarter.
- 33 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2022 and 4 closed out, a net change of +29 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2022 was Lion Point Capital, an estimated $12.7M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2022 was Stonepine Capital Management, an estimated $12.3M sold.
Based on aggregated 13F filings for Q1 2022.